7-OH (7-Hydroxymitragynine): The Opioid Sold at the Corner Store

7-OH, short for 7-hydroxymitragynine, is a compound that occurs in tiny amounts in the kratom plant and is now being concentrated and sold on its own in tablets, gummies, drink mixes, and shots. The FDA describes it as “an opioid that can be more potent than morphine.” It is on shelves in gas stations, smoke shops, and corner stores right now, and the federal rules meant to restrict it have been proposed but are not yet in effect.

What 7-OH Is, and How It Differs From Kratom

Kratom is an evergreen tree native to Southeast Asia. Its leaves contain alkaloids, which are naturally occurring plant compounds that act on the body, and the main one is called mitragynine. 7-OH is present in the leaf too, but only in small amounts. The FDA puts it at less than 2% of the total alkaloid content of natural kratom leaves.

7-OH also forms inside the body. NIDA explains that mitragynine breaks down into 7-OH once kratom is digested.

The products now being sold as 7-OH are a different thing altogether. An FDA scientific assessment states that the 7-OH in these products is likely produced by chemically converting mitragynine, the more plentiful alkaloid, into 7-OH through a process called oxidation. The plant is the starting material, but the product on the shelf is manufactured. Sarah Kawasaki, director of the Advancement in Recovery Program at Penn State Health, put it plainly in an interview published in August 2026: “It’s been synthetically isolated and manufactured.”

That distinction matters, and it is one federal regulators have drawn on purpose. The DEA has said its scheduling action targets concentrated and synthetic 7-OH products and is not intended to apply to natural kratom leaf containing only trace levels of 7-OH.

What 7-OH Does in the Body

The brain and body have receptors that opioids attach to, and it helps to think of them as switches that affect pain, alertness, and breathing. Morphine, oxycodone, and heroin all work by flipping those switches. So does 7-OH. NIDA confirms it acts on the same opioid receptors as those drugs. When they are flipped, a person feels pain relief, drowsiness, and often a sense of calm or euphoria.

The difference between 7-OH and the plant it comes from is how hard it flips those switches. The FDA’s scientific assessment found that 7-OH attaches to these receptors tightly and turns them on fully rather than partially. In testing cited by the FDA, it turned them on to nearly the same degree as morphine. In its consumer materials, the FDA states that 7-OH is 13 times more potent than morphine.

The biggest danger is what opioids do to breathing. They slow it down, and if it slows far enough, the body stops getting the oxygen it needs and a person can die. The medical term for this is respiratory depression, and it is what makes an opioid overdose fatal. In animal testing reported in the FDA assessment, 7-OH was more than three times as potent as morphine at slowing breathing, which means a much smaller amount produced the same effect. NIDA notes that in laboratory studies, this effect on breathing can be reversed by naloxone, the overdose-reversal medication used for other opioids.

Overdose is not the only risk. The FDA reports that people using 7-OH products have experienced addiction, anxiety, depression, stomach and digestive problems, trouble sleeping, seizures, and withdrawal symptoms such as restlessness, body aches, fatigue, irritability, and cold sweats.

Why These Products Are So Much Stronger Than the Plant

In the kratom leaf, 7-OH is a trace ingredient. The FDA’s assessment states that 7-OH typically occurs in botanical kratom in amounts no more than about 0.01 to 0.04 percent by dry weight. In a study of 341 kratom samples cited in that assessment, the 7-OH content ranged from too small to measure up to a maximum of 0.21 percent, with an average of 0.01 percent. The leaf simply does not carry much of it.

There is a second reason the plant behaves differently. Some of the 7-OH in a person’s system after using kratom is not swallowed at all; it is made by the body as mitragynine breaks down. NIDA notes that in general, neither kratom leaves nor mitragynine appear to cause the kind of breathing trouble that makes an opioid overdose life-threatening, and that the body’s conversion of mitragynine into 7-OH happens slowly enough to limit the effect on breathing.

Concentrated 7-OH products remove both of those brakes. The dose arrives directly, already in its stronger form, and at strengths the leaf does not reach. The FDA assessment cites testing that found one product, sold as pressed pills, contained 15 mg of 7-OH per pill, which the assessment describes as far greater than has been observed in any botanical kratom preparation to date.

This is not an accident of processing. Missouri’s Department of Health and Senior Services puts it bluntly, calling 7-OH a substance that “is engineered to be addictive. It is a potent opioid by design.”

Sold in Gas Stations, Smoke Shops, and Online

What makes 7-OH unusual is that no one needs a dealer to get it. The DEA describes these products as widely marketed online and sold in gas stations, convenience stores, and smoke shops. They come as tablets, gummies, drink mixes, and small liquid shots, sitting on the counter beside the energy drinks.

They are also cheap. One analysis cited in the FDA’s assessment found that most of the products reviewed, 82.2 percent, were chewable or under-the-tongue tablets, shots, or gummies, and that the average cost per recommended serving was $3.97.

How they look on the shelf matters too. Penn State Health describes 7-OH products as “often packaged with bright, energy-drink-style branding right at the counter.” The FDA has raised concern about forms that appeal to young people, including fruit-flavored gummies and ice cream cones, and has noted that these products are sometimes disguised or marketed as kratom, so a buyer may not know what is actually in the package.

None of this is authorized. In July 2025, the FDA sent warning letters to seven companies marketing 7-OH products, stating that 7-OH “is not lawful in dietary supplements and cannot be lawfully added to conventional foods.” The letters cited products making unapproved claims about relieving pain and managing anxiety. Those are the claims most likely to reach someone trying to handle pain or anxiety on their own.

The distance between a free sample and a daily habit can be short. Penn State Health reported in August 2026 on Michael Krause, who took a free sample offered at a store and described the effect as the same as a strong dose of prescription oxycodone. Within three months, he was spending $100 a day.

What the FDA and DEA Are Doing, and What Is Still Legal

Federal action on 7-OH started in the summer of 2025. In July of that year, the FDA sent warning letters to seven companies selling 7-OH products. Later the same month, the FDA recommended that 7-OH be scheduled under the Controlled Substances Act and released guidance for healthcare professionals and consumers. FDA Commissioner Marty Makary said at the time that “7-OH is an opioid that can be more potent than morphine.”

A year later, the DEA moved. On July 1, 2026, the DEA announced it was starting the process to temporarily place 7-OH above a set threshold into Schedule I, along with three related compounds that do not occur naturally in kratom: mitragynine pseudoindoxyl, MGM-15, and MGM-16. DEA Administrator Terrance Cole said the action “targets highly concentrated, synthetic 7-OH products, which pose a growing threat to public safety and health.”

The notice published in the Federal Register on July 6, 2026 set the proposed threshold at more than 0.050 percent 7-OH by dry weight, or more than 1.00 mg of 7-OH in a synthetic formulation. If the order takes effect, making, distributing, selling, and possessing the covered products becomes subject to the criminal, civil, and administrative provisions of the Controlled Substances Act.

Here is the part that matters for anyone reading this today. As of August 2026, that order has not taken effect. The comment period has closed, but what stands on the books is a proposal, not a ban. These products remain on shelves and available online while the process finishes.

It is also worth knowing that this has stalled before. In August 2016, the DEA published a notice of intent to place both mitragynine and 7-OH into Schedule I, and withdrew it that October. The current action is narrower, aimed at concentrated and synthetic 7-OH rather than the plant, but the outcome is not settled.

What to Do If You or Someone You Know Is Using 7-OH

Many people using 7-OH did not set out to use an opioid. They bought something at a counter that looked like a supplement or an energy product, and it helped with pain, or anxiety, or getting through the day. That is worth saying plainly, because the warning signs families usually watch for may not show up here. There is no dealer, no prescription, and no obvious moment where a line got crossed.

If that describes you or someone close to you, the useful question is what comes next. Dependence can build in a matter of weeks, and withdrawal is the point where most people end up going back to it. A physician, a counsellor, or a treatment or community program can help manage that stretch, and there is no reason to go through it alone.

If someone is still using, keeping naloxone on hand is a reasonable precaution, the same as it would be with any other opioid. It is also worth reading labels carefully on anything bought as kratom, since the FDA has warned that these products are sometimes disguised or marketed under that name.

The rules around 7-OH are still being written, and store shelves have not caught up. Until they do, the safest assumption is the simplest one. If a product contains concentrated 7-OH, it is an opioid, and it deserves to be treated like one.